Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diclofenac/eperisone - Eisai

Drug Profile

Diclofenac/eperisone - Eisai

Alternative Names: Eperisone/diclofenac - Eisai; Eprisan D SR

Latest Information Update: 27 Jun 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Class Muscle relaxants; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Piperidines; Propiophenones; Small molecules
  • Mechanism of Action Calcium channel antagonists; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Back pain

Most Recent Events

  • 27 Jun 2019 Chemical structure information added
  • 30 Sep 2011 Eisai completes a phase III trial in Back pain in India (NCT01300312; CTRI/2010/091/002934)
  • 28 Feb 2011 Phase-III clinical trials in Back pain in India (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top